Last reviewed · How we verify
High dose of Unfractionated Heparin
High dose of Unfractionated Heparin is a Anticoagulant Small molecule drug developed by University of Patras. It is currently FDA-approved for Acute coronary syndrome, Pulmonary embolism, Deep vein thrombosis.
High-dose unfractionated heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors.
High-dose unfractionated heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates thrombin and other clotting factors. Used for Acute coronary syndrome, Pulmonary embolism, Deep vein thrombosis.
At a glance
| Generic name | High dose of Unfractionated Heparin |
|---|---|
| Sponsor | University of Patras |
| Drug class | Anticoagulant |
| Target | Thrombin (Factor IIa), Factor Xa, antithrombin III |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Unfractionated heparin (UFH) is a naturally occurring glycosaminoglycan that binds to antithrombin III and dramatically accelerates its inhibition of thrombin (Factor IIa) and Factor Xa. At high doses, UFH provides rapid anticoagulation suitable for acute thrombotic events and is commonly used in hospital settings for conditions requiring immediate anticoagulation. The high-dose formulation achieves therapeutic anticoagulation quickly, making it suitable for acute coronary syndromes, pulmonary embolism, and deep vein thrombosis.
Approved indications
- Acute coronary syndrome
- Pulmonary embolism
- Deep vein thrombosis
- Acute thrombosis prevention
Common side effects
- Bleeding
- Thrombocytopenia
- Heparin-induced thrombocytopenia (HIT)
- Osteoporosis (with prolonged use)
- Hyperkalemia
Key clinical trials
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. (PHASE3)
- Heparin vs Placebo for Cardiac Catheterization (PHASE3)
- HAI-Floxuridine, or SIRT, Combined With Gemox For Patients With Intra-Hepatic Cholangiocarcinoma Not Amenable to Resection (TOMCAT) (PHASE2)
- Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass (PHASE3)
- LDA and LMWH vs LDA Alone in High-risk Patients for Preeclampsia Prevention (PHASE4)
- A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High dose of Unfractionated Heparin CI brief — competitive landscape report
- High dose of Unfractionated Heparin updates RSS · CI watch RSS
- University of Patras portfolio CI
Frequently asked questions about High dose of Unfractionated Heparin
What is High dose of Unfractionated Heparin?
How does High dose of Unfractionated Heparin work?
What is High dose of Unfractionated Heparin used for?
Who makes High dose of Unfractionated Heparin?
What drug class is High dose of Unfractionated Heparin in?
What development phase is High dose of Unfractionated Heparin in?
What are the side effects of High dose of Unfractionated Heparin?
What does High dose of Unfractionated Heparin target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Thrombin (Factor IIa), Factor Xa, antithrombin III
- Manufacturer: University of Patras — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Pulmonary embolism
- Indication: Drugs for Deep vein thrombosis
- Compare: High dose of Unfractionated Heparin vs similar drugs
- Pricing: High dose of Unfractionated Heparin cost, discount & access